Form 10-Q BridgeBio Pharma, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
August 2, 2024 12:19 PM EDTCiti analyst David Lebowitz lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $45.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "BridgeBio announced 2Q24 earnings, provided an update on its pipeline, and pointed toward key recent achievements. Mgt. also highlighted... More
